Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation
Related Experiment Video
Updated: Apr 30, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Ali Eishei Oskuei1, Khadijeh Makhdoomi2, Saeed Abkhiz3
1Associate Professor of Hematology and Oncology, Uromia University of Medical Sciences, Iran. Makhdoomikhadijeh@yahoo.com.
Abstract:
Chronic Myelogenic Leukemia (CML) is a rare malignant disorder after solid organ transplantation, especially in renal transplant recipients. Imatinib Mesylate is currently approved as first line treatment of CML. Most reports on CML are from kidney recipients who received azathioprine in combination with cyclosporine and prednisolone as immunosuppressive therapy. We report a case with CML who was treated with Mycophenolate Mofetil.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction

